Shares of Cel-Sci Corporation (NYSE: CVM) are running sharply higher today, on rumors that the biotech company may be bought out by a larger pharmaceutical company.
As of now, there is no definitive rumor on which company may acquired CVM.
CVM has a roughly $130 million market cap, so it is cheap based on a market cap metric.
CEL-SCI Corporation is best known for its Multikine drug, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients.
Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors.
Shares of CVM are up 7 cents or nearly $13 today to 62 cents.